{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T21:00:54Z","timestamp":1697317254239},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2004,3,1]],"date-time":"2004-03-01T00:00:00Z","timestamp":1078099200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Osteoporos Rep"],"published-print":{"date-parts":[[2004,3]]},"DOI":"10.1007\/s11914-004-0012-4","type":"journal-article","created":{"date-parts":[[2007,5,25]],"date-time":"2007-05-25T22:47:20Z","timestamp":1180133240000},"page":"31-36","source":"Crossref","is-referenced-by-count":7,"title":["Is it ethical to use placebos in osteoporosis clinical trials?"],"prefix":"10.1007","volume":"2","author":[{"given":"Nelson B.","family":"Watts","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"12_CR1","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1359\/jbmr.2003.18.6.1160","volume":"18","author":"A Capron","year":"2003","unstructured":"Capron A, Donaldson S, Raisz LG, Swift S: Osteoporosis panel summary. J Bone Miner Res 2003, 18:1160\u20131162.","journal-title":"J Bone Miner Res"},{"key":"12_CR2","doi-asserted-by":"crossref","first-page":"455","DOI":"10.7326\/0003-4819-133-6-200009190-00014","volume":"133","author":"R Temple","year":"2000","unstructured":"Temple R, Ellenberg SS: Placebo-controlled trials and activecontrol trials in the evaluation of new treatments. Part 1: ethical and scientific issues. Ann Intern Med 2000, 133:455\u2013463. A good discussion of ethical and scientific issues surrounding clinical trials.","journal-title":"Ann Intern Med"},{"key":"12_CR3","doi-asserted-by":"crossref","first-page":"464","DOI":"10.7326\/0003-4819-133-6-200009190-00015","volume":"133","author":"SS Ellenberg","year":"2000","unstructured":"Ellenberg SS, Temple R: Placebo-controlled trials and activecontrol trials in the evaluation of new treatments. Part 2: practical issues and specific cases. Ann Intern Med 2000, 133:464\u2013470. A good discussion of practical issues of clinical trials.","journal-title":"Ann Intern Med"},{"key":"12_CR4","unstructured":"Guidelines for preclinical and clinical evaluation of agents in the prevention or treatment of postmenopausal osteoporosis. Available at http:\/\/www.fda.gov\/cder\/guidance\/osteo.pdf."},{"key":"12_CR5","unstructured":"Guidelines for Preclinical Evaluation and Clinical Trials in Osteoporosis Geneva, Switzerland: World Health Organization; 1998."},{"key":"12_CR6","unstructured":"European Agency for the Evaluation of Medicinal Production, Committee for Proprietary Medicinal Products CPMP: Note for guidance on postmenopausal osteoporosis in women. Available at http:\/\/www.emea.eu.int\/pdfs\/human\/ewp\/055295en.pdf."},{"key":"12_CR7","unstructured":"World Medical Association: Declaration of Helsinki. Available at http:\/\/www.wma.net\/e\/policy\/b3.htm. This is the \"Declaration of Helsinki.\" Article 29 sets forth the position of the World Medical Association on clinical trials."},{"key":"12_CR8","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1002\/jbmr.5650111218","volume":"11","author":"RR Recker","year":"1996","unstructured":"Recker RR, Hinders S, Davies KM, et al.: Correcting calcium nutritional deficiency prevents spine fractures in elderly women. J Bone Miner Res 1996, 11:1961\u20131966.","journal-title":"J Bone Miner Res"},{"key":"12_CR9","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1056\/NEJM199709043371003","volume":"337","author":"B Dawson-Hughes","year":"1997","unstructured":"Dawson-Hughes B, Harris SS, Krall EA, Dallal G: Effects of calcium and vitamin D supplementation on bone density in men and women 65 years of age and older. N Engl J Med 1997, 337:670\u2013676.","journal-title":"N Engl J Med"},{"key":"12_CR10","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","volume":"348","author":"DM Black","year":"1996","unstructured":"Black DM, Cummings SR, Karpf DB, et al.:Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996, 348:1535\u20131541.","journal-title":"Lancet"},{"key":"12_CR11","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.282.7.637","volume":"282","author":"B Ettinger","year":"1999","unstructured":"Ettinger B, Black DM, Mitlak BH, et al.:Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 1999, 282:637\u2013645.","journal-title":"JAMA"},{"key":"12_CR12","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","volume":"282","author":"ST Harris","year":"1999","unstructured":"Harris ST, Watts NB, Genant HK, et al.:Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. JAMA 1999, 282:1344\u20131352.","journal-title":"JAMA"},{"key":"12_CR13","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0002-9343(00)00490-3","volume":"102","author":"CH Chesnut III","year":"2000","unstructured":"Chesnut CH, III, Silverman S, Andriano K, et al.: A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the Prevent Recurrence of Osteoporotic Fractures Study. Am J Med 2000, 102:267\u2013276.","journal-title":"Am J Med"},{"key":"12_CR14","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","volume":"344","author":"RM Neer","year":"2001","unstructured":"Neer RM, Arnaud CD, Zanchetta JR, et al.:Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001, 344:1434\u20131441.","journal-title":"N Engl J Med"},{"key":"12_CR15","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","volume":"280","author":"SR Cummings","year":"1998","unstructured":"Cummings SR, Black DM, Thompson DE, et al.:Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998, 280:2077\u20132082.","journal-title":"JAMA"},{"key":"12_CR16","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s001980050010","volume":"11","author":"JY Reginster","year":"2000","unstructured":"Reginster JY, Minne HW, Sorensen OH, et al.:Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 2000, 11:83\u201391.","journal-title":"Osteoporos Int"},{"key":"12_CR17","doi-asserted-by":"crossref","first-page":"919","DOI":"10.7326\/0003-4819-114-11-919","volume":"114","author":"PD Ross","year":"1991","unstructured":"Ross PD, Davis JW, Epstein RS, Wasnich RD: Pre-existing fractures and bone mass predict vertebral fracture incidence in women. Ann Intern Med 1991, 114:919\u2013923.","journal-title":"Ann Intern Med"},{"key":"12_CR18","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1001\/jama.285.3.320","volume":"285","author":"R Lindsay","year":"2001","unstructured":"Lindsay R, Silverman SL, Cooper C, et al.:Risk of new vertebral fracture in the year following a fracture. JAMA 2001, 285:320\u2013323.","journal-title":"JAMA"},{"issue":"suppl","key":"12_CR19","first-page":"S220","volume":"16","author":"SR Cummings","year":"2001","unstructured":"Cummings SR, Modelska K, Nevitt MC, Black DM: Are placebo-controlled trials ethical for women with osteoporosis [abstract]? J Bone Miner Res 2001, 16(suppl):S220.","journal-title":"J Bone Miner Res"},{"key":"12_CR20","doi-asserted-by":"crossref","first-page":"793","DOI":"10.7326\/0003-4819-128-10-199805150-00001","volume":"128","author":"MC Nevitt","year":"1998","unstructured":"Nevitt MC, Ettinger B, Black DM, et al.:The association of radiographically detected vertebral fractures with back pain and function: a prospective study. Ann Intern Med 1998, 128:793\u2013800.","journal-title":"Ann Intern Med"},{"key":"12_CR21","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.1002\/1529-0131(200111)44:11<2611::AID-ART441>3.0.CO;2-N","volume":"44","author":"SL Silverman","year":"2001","unstructured":"Silverman SL, Minshall ME, Shen W, et al.:The relationship of health-related quality of life to prevalent and incident vertebral fractures in postmenopausal women with osteoporosis: results from the multiple outcomes of raloxifene evaluation study. Arthritis Rheum 2001, 44:2611\u20132619.","journal-title":"Arthritis Rheum"},{"key":"12_CR22","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1093\/oxfordjournals.aje.a116756","volume":"137","author":"C Cooper","year":"1993","unstructured":"Cooper C, Atkinson EJ, Jacobsen SJ, et al.:Population-based study of survival after osteoporotic fractures. Am J Epidemiol 1993, 137:1001\u20131005.","journal-title":"Am J Epidemiol"},{"key":"12_CR23","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1001\/archinte.159.11.1215","volume":"159","author":"DM Kado","year":"1999","unstructured":"Kado DM, Browner WS, Palermo L, et al.:Vertebral fractures and mortality in older women: a prospective study. Study of Osteoporotic Fractures Research Group. Arch Intern Med 1999, 159:1215\u20131220.","journal-title":"Arch Intern Med"},{"key":"12_CR24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1359\/jbmr.2002.17.1.1","volume":"17","author":"S Sarkar","year":"2002","unstructured":"Sarkar S, Mitlak BH, Wong MM, et al.:Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J Bone Miner Res 2002, 17:1\u201310.","journal-title":"J Bone Miner Res"},{"key":"12_CR25","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1007\/s001980170020","volume":"12","author":"NH Bjarnason","year":"2001","unstructured":"Bjarnason NH, Sarkar S, Duong T, et al.:Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years raloxifene treatment in postmenopausal osteoporosis. Osteoporos Int 2001, 12:922\u201330.","journal-title":"Osteoporos Int"},{"key":"12_CR26","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1359\/jbmr.2003.18.6.1051","volume":"18","author":"R Eastell","year":"2003","unstructured":"Eastell R, Barton I, Hannon RA, et al.:Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 2003, 18:1051\u20131056.","journal-title":"J Bone Miner Res"},{"key":"12_CR27","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1515\/CCLM.2000.192","volume":"38","author":"TJ Cleophas","year":"2000","unstructured":"Cleophas TJ, Zwinderman AH: Limitations of randomized clinical trials: proposed alternative designs. Clin Chem Lab Med 2000, 38:1217\u20131223. An excellent discussion of design issues in clinical trials.","journal-title":"Clin Chem Lab Med"},{"key":"12_CR28","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/0002-9343(87)90069-6","volume":"82","author":"F Rosner","year":"1987","unstructured":"Rosner F: The ethics of randomized clinical trials. Am J Med 1987, 82:283\u2013290.","journal-title":"Am J Med"},{"key":"12_CR29","doi-asserted-by":"crossref","unstructured":"Watts NB, Lindsay R, Li Z, et al.: Use of matched historical controls to evaluate the anti-fracture efficacy of once-a-week risedronate. Osteoporos Int 2003, 437\u2013441. An example of the use of historical control subjects to evaluate antifracture efficacy in a study in which there was no simultaneous placebo group.","DOI":"10.1007\/s00198-003-1401-8"},{"key":"12_CR30","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s001980070097","volume":"11","author":"R Dowd","year":"2000","unstructured":"Dowd R, Recker RR, Heaney RP: Study subjects and ordinary patients. Osteoporos Int 2000, 11:533\u2013536.","journal-title":"Osteoporos Int"},{"key":"12_CR31","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1001\/jama.286.22.2865","volume":"286","author":"CH Chesnut III","year":"2001","unstructured":"Chesnut CH, III: Osteoporosis: an under-diagnosed disease. JAMA 2001, 286:2865\u20132866.","journal-title":"JAMA"},{"key":"12_CR32","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s001980070078","volume":"11","author":"SH Gehlbach","year":"2000","unstructured":"Gehlbach SH, Bigelow C, Heimisdottir M, et al.:Recognition of vertebral fracture in a clinical setting. Osteoporos Int 2000, 11:577\u2013582.","journal-title":"Osteoporos Int"},{"key":"12_CR33","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1001\/archinte.162.19.2217","volume":"162","author":"GM Kiebzak","year":"2002","unstructured":"Kiebzak GM, Beinart GA, Perser K, et al.:Under-treatment of osteoporosis in men with hip fracture. Arch Intern Med 2002, 162:2217\u20132222.","journal-title":"Arch Intern Med"},{"key":"12_CR34","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s001980200052","volume":"13","author":"JA Kanis","year":"2002","unstructured":"Kanis JA, Oden A, Johnell O, et al.:Uncertain future of trials in osteoporosis. Osteoporos Int 2002, 13:443\u2013449. A superb exposition of problems with superiority and non-inferiority trials and the sample size needed for various types of studies.","journal-title":"Osteoporos Int"},{"key":"12_CR35","volume-title":"The Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects of Research","author":"National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research","year":"1979","unstructured":"National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research: The Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects of Research. Washington, DC: US Government Printing Office; 1979."},{"key":"12_CR36","first-page":"36","volume":"1","author":"M Russell-Einhorn","year":"1998","unstructured":"Russell-Einhorn M, Ellis GB: Human subject protections in the United States: perspectives from the Office for Protection from Research Risks. J Biolaw Bus 1998, 1:36\u201338.","journal-title":"J Biolaw Bus"},{"key":"12_CR37","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1097\/00005650-200209001-00005","volume":"40","author":"M Holmes-Rovner","year":"2002","unstructured":"Holmes-Rovner M, Wills CE: Improving informed consent: insights from behavioral decision research. Med Care 2002, 40:308.","journal-title":"Med Care"},{"key":"12_CR38","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1136\/jme.29.1.4","volume":"29","author":"O O\u2019Neill","year":"2003","unstructured":"O\u2019Neill O: Some limits of informed consent. J Med Ethics 2003, 29:4\u20137.","journal-title":"J Med Ethics"}],"container-title":["Current Osteoporosis Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11914-004-0012-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11914-004-0012-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11914-004-0012-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T00:31:51Z","timestamp":1559435511000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11914-004-0012-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,3]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2004,3]]}},"alternative-id":["12"],"URL":"https:\/\/doi.org\/10.1007\/s11914-004-0012-4","relation":{},"ISSN":["1544-1873","1544-2241"],"issn-type":[{"value":"1544-1873","type":"print"},{"value":"1544-2241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,3]]}}}